Ocular Therapeutix OCUL Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$290.5M-9.2% | -$265.94M-6.5% | -$249.67M-15.2% | -$216.75M-12.5% | -$192.71M+0.4% | ||
| $4.63M+7.0% | $4.32M+7.4% | $4.03M+2.8% | $3.92M+1.8% | $3.85M+1.6% | ||
| $48.31M+11.9% | $43.18M+10.7% | $39.02M+14.9% | $33.97M-4.5% | $35.59M+7.5% | ||
| $3.34M-1.6% | $3.4M-2.3% | $3.48M+4.1% | $3.34M+4.3% | $3.2M-14.2% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | -$1.33M-121% | ||
| $468K-10.7% | $524K-51.6% | $1.08M— | —— | —— | ||
| $2.83M+418% | -$887K— | —— | —— | —— | ||
| $1.95M-62.8% | $5.25M-27.9% | $7.28M— | —— | —— | ||
| —— | —— | -$5.2M-320% | $2.36M+27.0% | $1.86M-67.2% | ||
| —— | —— | —— | -$269K-0.7% | -$267K-1.9% | ||
| $367K+122% | -$1.66M-78.4% | -$929K-26.6% | -$734K+20.8% | -$927K+21.8% | ||
| -$226.21M-10.4% | -$204.88M-7.8% | -$190.06M-8.1% | -$175.9M-20.9% | -$145.46M-8.0% | ||
| $14.74M+22.7% | $12.01M+28.1% | $9.37M+170% | $3.47M+17.0% | $2.97M+130% | ||
| -$14.61M-23.0% | -$11.88M-28.5% | -$9.24M-177% | -$3.34M-12.6% | -$2.97M-130% | ||
| $16.66M-18.9% | $20.54M-4.9% | $21.6M— | —— | —— | ||
| $557.83M-0.7% | $561.72M+381% | $116.86M+5.6% | $110.68M+634% | $15.07M-95.5% | ||
| $317.02M-8.1% | $344.96M— | —— | —— | —— | ||
| $9.08M+0.5% | $9.03M-10.8% | $10.12M-2.6% | $10.39M-3.0% | $10.71M-50.3% | ||
| $3.34M-1.6% | $3.4M-2.3% | $3.48M+4.1% | $3.34M+4.3% | $3.2M-14.2% | ||
| —— | —— | —— | —— | —— | ||
| $612K+145% | -$1.36M— | —— | —— | —— | ||
| $367K+122% | -$1.66M-78.4% | -$929K-26.6% | -$734K+20.8% | -$927K+21.8% | ||
| —— | —— | -$5.2M-320% | $2.36M+27.0% | $1.86M-67.2% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | -$269K-0.7% | -$267K-1.9% | ||
| $367K+122% | -$1.66M-78.4% | -$929K-26.6% | -$734K+20.8% | -$927K+21.8% | ||
| —— | —— | —— | —— | —— | ||
| -$240.94M-11.1% | -$216.89M-8.8% | -$199.44M-11.2% | -$179.37M-20.8% | -$148.43M-9.2% | ||
| -$240.94M-11.1% | -$216.89M-8.8% | -$199.44M-11.2% | -$179.37M-20.8% | -$148.43M-9.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Ocular Therapeutix generate?
- Ocular Therapeutix (OCUL) generated -$226.2M in operating cash flow over the trailing twelve months.
- What is Ocular Therapeutix's free cash flow?
- After $14.7M of capital expenditures, Ocular Therapeutix's free cash flow was -$240.9M over the trailing twelve months, down 62.3% year over year.
- Where does Ocular Therapeutix's cash flow data come from?
- Every line is extracted from Ocular Therapeutix's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
